


IN THE CLAIMS:

Please cancel claims 1-23 without prejudice or disclaimer, and add new claims 24-46.

--24. (New) A compound of the formula (I):




AT

wherein:

A is a member selected from the group consisting of:

benzene, thiophene, furan, pyrrole, indole,



wherein

each B is independently selected from the group consisting of $-C(-R^1)(-R^2)-$, $-O-$ and $-N(-J-R^3)-$, wherein not more than one B in any ring is either $-O-$ or $-N(-J-R^3)-$;

each m and n is independently an integer from 0 to 4;

each q is independently an integer from 0 to 8;

Y is a member selected from the group consisting of $-(CH_2)_q-$, $-(CH_2)_mO-$ and $-(CH_2)_mN(-J^1)-R^4$;

Z is a member selected from the group consisting of $-(CH_2)_nC(=O)-NHOH$, $-(CH_2)_nCOOH$, $-(CH_2)_nCOOMe$ and $-(CH_2)_nCOOEt$;

L is a member selected from the group consisting of $-(CH_2)_q-$, $-(CH_2)_mO-$ and $-(CH_2)_mN(-J^2)-R^5$;

J, J^1 and J^2 are each independently selected from the group consisting of $C(=O)$ and a bond;

R^1 is a member selected from the group consisting of H, $-N(-J^3-R^6)(-J^4-R^7)$ and $-O-J^5-R^8$, wherein J^3 , J^4 and J^5 are each independently selected from the group consisting of $-C(=O)-$ and a bond, wherein at least one of J^3 and J^4 is a bond;

R^2 is a member selected from the group consisting of H, $-N(-J^6-R^9)(-J^7-R^{10})$ and $-O-J^8-R^{11}$, wherein J^6 , J^7 and J^8 are independently selected from the group consisting of $-C(=O)-$ and a bond, wherein at least one of J^6 and J^7 is a bond;

R^3 is a member selected from the group consisting of H, C_1-C_8 alkyl, CF_3 and $O-R^{12}$;

R^4 is a member selected from the group consisting of H, C_1-C_8 alkyl, CF_3 and $O-R^{13}$;

R^5 is a member selected from the group consisting of H, C_1-C_8 alkyl, CF_3 and $O-R^{14}$;

R^6 is a member selected from the group consisting of H, C_1-C_8 alkyl, CF_3 and $O-R^{15}$;

R^7 is a member selected from the group consisting of H, C_1-C_8 alkyl, CF_3 and $O-R^{16}$;

R^8 is a member selected from the group consisting of H, C_1-C_8 alkyl, CF_3 and $O-R^{17}$;

R^9 is a member selected from the group consisting of H, C_1-C_8 alkyl, CF_3 and $O-R^{18}$;


R^{10} is a member selected from the group consisting of H, C_1 - C_8 alkyl, CF_3 and $O-R^{19}$;

R^{11} is a member selected from the group consisting of H, C_1 - C_8 alkyl, CF_3 and $O-R^{20}$;


R^{12} , R^{13} , R^{14} , R^{15} , R^{16} , R^{17} , R^{18} , R^{19} and R^{20} are each independently selected from the group consisting of C_1 - C_4 alkyl, cycloalkyl and benzyl;

and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives thereof.

25. (New) The compound according to claim 24 wherein A is a member selected from the group consisting of :




26. (New) The compound according to claim 24 wherein A is a member selected from the group consisting of:




Y is a member selected from the group consisting of $-(CH_2)_q-$ and $-(CH_2)_mO-$;
L is a member selected from the group consisting of $-(CH_2)_q-$ and $-(CH_2)_mO-$; and
 R^1 is a member selected from the group consisting of H and $-O-J^5-R^8$; and
 R^2 is a member selected from the group consisting of H and $-O-J^8-R^{11}$;
and all pharmaceutically acceptable salts thereof.

27. (New) The compound according to claim 24, wherein A is a member selected from the group consisting of:



Y is a member selected from the group consisting of $-(CH_2)_q-$ and $-(CH_2)_mO-$;
L is a member selected from the group consisting of $-(CH_2)_q-$ and $-(CH_2)_mO-$; and
 R^1 is a member selected from the group consisting of H and $-O-J^5-R^8$; and
 R^2 is a member selected from the group consisting of H and $-O-J^8-R^{11}$;
and all pharmaceutically acceptable salts thereof.

28. (New) The compound according to claim 24 wherein A is a member selected from the group consisting of:



wherein

each B is CH_2 ;

Y is a member selected from the group consisting of $-(CH_2)_q-$ and $-(CH_2)_mO-$;

Z is $-(CH_2)_n-C(=O)-NHOH$;

L is $-(CH_2)_q-$;

each m and n is independently an integer from 0 to 4; and

each q is independently an integer from 0 to 8;

and all pharmaceutically acceptable salts thereof.

29. (New) A pharmaceutical composition comprising an effective amount of a compound according to claim 24, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier.

A1 30. (New) The pharmaceutical composition comprising an effective amount of a compound according to claim 25, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier.

31. (New) The pharmaceutical composition comprising an effective amount of a compound according to claim 26, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier.

32. (New) The pharmaceutical composition comprising an effective amount of a compound according to claim 27, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier.

33. (New) The pharmaceutical composition comprising an effective amount of a compound according to claim 28, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier.

34. (New) A method of inhibiting adenylyl cyclase in a patient having a disease or condition modulated by elevated levels of adenylyl cyclase activity, comprising administering a composition according to claim 29 to said patient.

35. (New) A method of inhibiting adenylyl cyclase in a patient having a disease or condition modulated by elevated levels of adenylyl cyclase activity, comprising administering a composition according to claim 30 to said patient.

36. (New) A method of inhibiting adenylyl cyclase in a patient having a disease or condition modulated by elevated levels of adenylyl cyclase activity, comprising administering a composition according to claim 31 to said patient.

37. (New) A method of inhibiting adenylyl cyclase in a patient having a disease or condition modulated by elevated levels of adenylyl cyclase activity, comprising administering a composition according to claim 32 to said patient.

38. (New) A method of inhibiting adenylyl cyclase in a patient having a disease or condition modulated by elevated levels of adenylyl cyclase activity, comprising administering a composition according to claim 33 to said patient.

AI
39. (New) The method according to claim 34, further comprising inhibiting or preventing a patient's fibroproliferative vasculopathy following vascular injury or a vascular surgical operation, wherein said composition is administered to a patient in an effective amount subsequent to a vascular injury, or subsequent to a vascular surgical operation.

40. (New) The method according to claim 39 wherein the composition is administered for one to two weeks after the injury or surgical operation.

41. (New) The method according to claim 40 wherein fibroproliferative vasculopathy is caused by chronic allograft rejection and vascular restenosis following vascular trauma.

42. (New) A method of treating congestive heart failure comprising administering an effective amount of a pharmaceutical composition according to claim 29 to a patient in need thereof.

43. (New) A method of treating congestive heart failure comprising administering an effective amount of a pharmaceutical composition according to claim 30 to a patient in need thereof.